Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Topical immunotherapy with DPCP is most effective for certain alopecia areata types, with success linked to age and disease duration, and influenced by a gene polymorphism.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Trichoscopy helps tell apart alopecia areata and trichotillomania in Asians by looking at specific hair and scalp features.

A woman's chronic headaches and hair loss were cured by treating her syphilis.

CD4 T cells need IFN-γ to cause hair loss in alopecia areata.

Erianin may effectively treat alopecia areata by targeting the immune system.

Alopecia areata is an autoimmune condition causing hair loss, influenced by genetics, stress, and diet, and may be prevented by a high soy oil diet.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Platelet-rich plasma treatment significantly increased hair regrowth and decreased discomfort in alopecia patients, making it a potentially better and safer treatment option.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Skin grafts on mice can cause an immune response leading to hair loss, useful for studying human hair loss conditions.

Alopecia areata significantly lowers the quality of life, especially in emotional and mental health aspects.

No single treatment is consistently effective for alopecia areata, and more research is needed.

Alopecia areata is a type of hair loss that can lead to complete baldness, often associated with other autoimmune conditions, and half of the cases may see hair return within a year.

Restoring hair bulb immune privilege is crucial for managing alopecia areata.

Trichoscopy helps diagnose and monitor alopecia areata by looking at a combination of specific hair and scalp features.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Animal models have helped understand hair loss from alopecia areata and find new treatments.

The Lexington LaserComb helped regrow hair in mice with a condition similar to human hair loss.

The 308-nm Excimer laser is effective and safe for treating patchy alopecia areata in children.

New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

A new type of rapid hair loss called ADTA usually gets better on its own within 6 months.

More research is needed to understand alopecia areata severity.

People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.

Alopecia areata involves immune system imbalances that may lead to depression and anxiety.

The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.